Cargando…

Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study

AIMS: Catheter ablation with a cryoballoon (CB) provides effective and durable pulmonary vein (PV) isolation (PVI) associated with encouraging clinical outcome data. The novel POLARx CB incorporates unique features, which may translate into improved safety, efficacy, and outcomes. The ICE-AGE-1 stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Heeger, Christian-Hendrik, Popescu, Sorin Stefan, Inderhees, Tim, Nussbickel, Noemi, Eitel, Charlotte, Kirstein, Bettina, Phan, Huong-Lan, Hatahet, Sascha, Subin, Behnam, Traub, Anna, Große, Niels, Kuck, Karl-Heinz, Vogler, Julia, Tilz, Roland R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468200/
https://www.ncbi.nlm.nih.gov/pubmed/37589146
http://dx.doi.org/10.1093/europace/euad248
_version_ 1785099188475789312
author Heeger, Christian-Hendrik
Popescu, Sorin Stefan
Inderhees, Tim
Nussbickel, Noemi
Eitel, Charlotte
Kirstein, Bettina
Phan, Huong-Lan
Hatahet, Sascha
Subin, Behnam
Traub, Anna
Große, Niels
Kuck, Karl-Heinz
Vogler, Julia
Tilz, Roland R
author_facet Heeger, Christian-Hendrik
Popescu, Sorin Stefan
Inderhees, Tim
Nussbickel, Noemi
Eitel, Charlotte
Kirstein, Bettina
Phan, Huong-Lan
Hatahet, Sascha
Subin, Behnam
Traub, Anna
Große, Niels
Kuck, Karl-Heinz
Vogler, Julia
Tilz, Roland R
author_sort Heeger, Christian-Hendrik
collection PubMed
description AIMS: Catheter ablation with a cryoballoon (CB) provides effective and durable pulmonary vein (PV) isolation (PVI) associated with encouraging clinical outcome data. The novel POLARx CB incorporates unique features, which may translate into improved safety, efficacy, and outcomes. The ICE-AGE-1 study aimed to assess the efficacy, safety, and 1-year clinical follow-up of the POLARx CB in comparison to the Arctic Front Advance Pro CB (AF-CB4). METHODS AND RESULTS: A total of 103 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who underwent POLARx-based PVI (POLARx group) were prospectively enrolled and were compared to 102 consecutive patients previously treated with the AF-CB4 (AF-CB4 group). The mean age was 68.7 ± 10.2 (POLARx) and 65.7 ± 12 (AF-CB4, P = 0.0551) years. A total of 412 (POLARx) and 404 (AF-CB4) PVs were identified. All PVs, except for one PV in the POLARx group, were successfully isolated. A significant difference regarding the mean minimal CB temperature reached using the POLARx CB (−56.1 ± 8.3°C) and AF-CB4 (−46.9 ± 10.1°C) was observed (P < 0.0001). Real-time PVI was visualized in 71% of PVs in the POLARx group and 46% of them in the AF-CB4 group (P < 0.001). The mean procedure time was comparable: 54.5 ± 17.1 min for POLARx and 59.4 ± 18.6 min for AF-CB4 (P = 0.0509). No differences were observed in terms of periprocedural complications. There were comparable rates in freedom of AF or atrial tachycardia recurrence after 12 months, beyond a 90-day long blanking period: 78.9% in the POLARx group vs. 77.2% in the AF-CB4 group (P = 0.804). CONCLUSION: The novel POLARx CB showed similar safety, efficacy, and 1-year recurrence-free survival rates compared to the AF-CB4. A higher rate of real-time electrical PV recordings and significantly lower balloon temperatures were observed using the POLARx as compared to AF-CB4.
format Online
Article
Text
id pubmed-10468200
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104682002023-08-31 Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study Heeger, Christian-Hendrik Popescu, Sorin Stefan Inderhees, Tim Nussbickel, Noemi Eitel, Charlotte Kirstein, Bettina Phan, Huong-Lan Hatahet, Sascha Subin, Behnam Traub, Anna Große, Niels Kuck, Karl-Heinz Vogler, Julia Tilz, Roland R Europace Clinical Research AIMS: Catheter ablation with a cryoballoon (CB) provides effective and durable pulmonary vein (PV) isolation (PVI) associated with encouraging clinical outcome data. The novel POLARx CB incorporates unique features, which may translate into improved safety, efficacy, and outcomes. The ICE-AGE-1 study aimed to assess the efficacy, safety, and 1-year clinical follow-up of the POLARx CB in comparison to the Arctic Front Advance Pro CB (AF-CB4). METHODS AND RESULTS: A total of 103 consecutive patients with paroxysmal or persistent atrial fibrillation (AF) who underwent POLARx-based PVI (POLARx group) were prospectively enrolled and were compared to 102 consecutive patients previously treated with the AF-CB4 (AF-CB4 group). The mean age was 68.7 ± 10.2 (POLARx) and 65.7 ± 12 (AF-CB4, P = 0.0551) years. A total of 412 (POLARx) and 404 (AF-CB4) PVs were identified. All PVs, except for one PV in the POLARx group, were successfully isolated. A significant difference regarding the mean minimal CB temperature reached using the POLARx CB (−56.1 ± 8.3°C) and AF-CB4 (−46.9 ± 10.1°C) was observed (P < 0.0001). Real-time PVI was visualized in 71% of PVs in the POLARx group and 46% of them in the AF-CB4 group (P < 0.001). The mean procedure time was comparable: 54.5 ± 17.1 min for POLARx and 59.4 ± 18.6 min for AF-CB4 (P = 0.0509). No differences were observed in terms of periprocedural complications. There were comparable rates in freedom of AF or atrial tachycardia recurrence after 12 months, beyond a 90-day long blanking period: 78.9% in the POLARx group vs. 77.2% in the AF-CB4 group (P = 0.804). CONCLUSION: The novel POLARx CB showed similar safety, efficacy, and 1-year recurrence-free survival rates compared to the AF-CB4. A higher rate of real-time electrical PV recordings and significantly lower balloon temperatures were observed using the POLARx as compared to AF-CB4. Oxford University Press 2023-08-17 /pmc/articles/PMC10468200/ /pubmed/37589146 http://dx.doi.org/10.1093/europace/euad248 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
Heeger, Christian-Hendrik
Popescu, Sorin Stefan
Inderhees, Tim
Nussbickel, Noemi
Eitel, Charlotte
Kirstein, Bettina
Phan, Huong-Lan
Hatahet, Sascha
Subin, Behnam
Traub, Anna
Große, Niels
Kuck, Karl-Heinz
Vogler, Julia
Tilz, Roland R
Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study
title Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study
title_full Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study
title_fullStr Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study
title_full_unstemmed Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study
title_short Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study
title_sort novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ice-age-1 study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468200/
https://www.ncbi.nlm.nih.gov/pubmed/37589146
http://dx.doi.org/10.1093/europace/euad248
work_keys_str_mv AT heegerchristianhendrik novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT popescusorinstefan novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT inderheestim novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT nussbickelnoemi novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT eitelcharlotte novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT kirsteinbettina novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT phanhuonglan novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT hatahetsascha novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT subinbehnam novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT traubanna novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT großeniels novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT kuckkarlheinz novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT voglerjulia novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study
AT tilzrolandr novelorestablishedcryoballoonablationsystemforpulmonaryveinisolationtheprospectiveiceage1study